KRAS Proteolysis Targeting Chimeras
AssigneePAQ Therapeutics Inc.
InventorsNan Ji, Hui Qiu, Ruoxi Lan
Life of this patent
Estimating the term…
Abstract
Provided herein are KRAS proteolysis targeting chimeras (PROTACs), compositions comprising the KRAS PROTACs, and methods of making and using the KRAS PROTACs, e.g., to promote degradation of KRAS and/or treat KRAS-associated cancers. In an embodiment, the KRAS PROTAC has the following structural formula: or a pharmaceutically acceptable salt thereof, wherein values for the variables are as described herein.
Claims43
A compound of the following formula:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is
- Ring A is (C5-C12) heterocyclyl;
- R5′ is hydroxy, —NH2, cyano, fluoro, or hydrogen;
- R5″ is hydrogen, halo, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6) hydroxyalkyl, or (C1-C6) cyanoalkyl;
- each R6 is independently halo, cyano, hydroxy, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6) hydroxyalkyl, or (C1-C6) cyanoalkyl;
- n is 1 or 2;
- m is 0, 1, 2, or 3;
- X1 is N or C(R10);
- R10 is hydrogen, halogen, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C2-C6)alkenyl, (C2-C6)alkynyl, —CN, (C1-C6)alkoxy, —S—(C1-C6)alkyl or —S—(C1-C6)haloalkyl;
- Y′ is —(C1-C3)alkylene-O-#, (C1-C3)alkylene-N(H)-#, or (C1-C3)alkylene-N ((C1-C3)alkyl)-#, or is absent;
- # indicates point of attachment of Y′ to L′;
- R3 is (C6-C14)aryl or (C5-C14) heteroaryl, wherein the (C6-C14)aryl or
- (C5-C14) heteroaryl is optionally substituted with one or more R14;
- R4 is hydrogen, halogen or (C1-C3)alkyl;
- each R14 is independently halogen, cyano, hydroxy, (C1-C4)alkyl, —S—(C1-C3)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C2-C4) hydroxyalkynyl, (C1-C3) cyanoalkyl, triazolyl, (C1-C3)haloalkyl, —O—(C1-C3)haloalkyl, —S—(C1-C3)haloalkyl,
- (C1-C3)alkoxy, (C1-C3) hydroxyalkyl, —CH2C(O)N(R11)2, (C3-C4)alkynyl-N(R11)2, N (R11)2, deutero (C2-C4)alkynyl, (C1-C3)alkoxy (C1-C3)haloalkyl, or
- (C3-C6) cycloalkyl, wherein the (C3-C6) cycloalkyl is optionally substituted with halogen or (C1-C3)alkyl;
- L′ is a covalent bond or a bivalent, saturated or unsaturated, straight or branched C1-C25 hydrocarbon chain wherein 0-10 methylenes of L′ are replaced by X;
- each X is independently-O—, —N(R)—, —S—, —OC(O)—, —C(O)—, —C(H)(F)—, —C(F)2—, -Cy-, —S(O)—, —S(O)2—, —N(R) S (O)2—, —N(R)C(O)—, —OC(O)N(R)—, —N(R)C(O)N(R)—,
- each-Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-11 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- each R is independently hydrogen or (C1-C3)alkyl;
- r is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
- and
- Degron is
- wherein one or more of the hydrogen atoms on the benzene ring of the Degron is optionally replaced with a fluorine atom,
- provided the compound is not
- or a salt thereof.
(canceled)
4-6. (canceled)
(canceled)
10-12. (canceled)
15-23. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
43-44. (canceled)
46-73. (canceled)
A compound selected from;
- or a pharmaceutically acceptable salt thereof.
A compound selected from:
- or a pharmaceutically acceptable salt thereof.
(canceled)
81-88. (canceled)
Dependencies are inferred from the claim text.